ZNF626

Summary

ZNF626 (zinc finger protein 626, HGNC:30461) is a protein-coding gene on chromosome 19p12, encoding Zinc finger protein 626 (Q68DY1). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of DNA-templated transcription. Predicted to be located in nucleus.

Source: NCBI Gene 199777 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 117 total
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• MANE Select transcript: NM_001076675

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30461
Approved symbol	ZNF626
Name	zinc finger protein 626
Location	19p12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000188171
Ensembl biotype	protein_coding
Entrez	199777

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000291750, ENST00000595405, ENST00000601440

RefSeq mRNA: 2 — MANE Select: NM_001076675 NM_001076675, NM_145297

CCDS: CCDS32976, CCDS42535

Canonical transcript exons

ENST00000601440 — 4 exons

Exon	Start	End
ENSE00003033830	20619939	20625650
ENSE00003142970	20661444	20661571
ENSE00003489667	20646279	20646405
ENSE00003502637	20645684	20645779

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 98.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.3391 / max 309.0581, expressed in 1449 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180200	12.5942	1441
180198	0.3995	211
180199	0.3454	187

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	98.87	gold quality
calcaneal tendon	UBERON:0003701	91.16	gold quality
tendon	UBERON:0000043	88.07	gold quality
adrenal tissue	UBERON:0018303	86.93	gold quality
tendon of biceps brachii	UBERON:0008188	84.27	silver quality
smooth muscle tissue	UBERON:0001135	82.16	gold quality
left ovary	UBERON:0002119	81.89	gold quality
oocyte	CL:0000023	81.79	gold quality
ganglionic eminence	UBERON:0004023	81.75	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.57	gold quality
islet of Langerhans	UBERON:0000006	81.42	gold quality
ovary	UBERON:0000992	80.87	gold quality
gall bladder	UBERON:0002110	80.87	gold quality
ventricular zone	UBERON:0003053	80.75	gold quality
cortical plate	UBERON:0005343	80.49	gold quality
medial globus pallidus	UBERON:0002477	80.42	gold quality
right ovary	UBERON:0002118	80.33	gold quality
secondary oocyte	CL:0000655	80.29	gold quality
endometrium	UBERON:0001295	80.05	gold quality
lymph node	UBERON:0000029	79.87	gold quality
corpus callosum	UBERON:0002336	79.58	gold quality
urinary bladder	UBERON:0001255	79.31	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.91	gold quality
sperm	CL:0000019	78.78	silver quality
adrenal gland	UBERON:0002369	78.76	gold quality
left adrenal gland	UBERON:0001234	78.58	gold quality
right adrenal gland cortex	UBERON:0035827	78.56	gold quality
right adrenal gland	UBERON:0001233	78.53	gold quality
left adrenal gland cortex	UBERON:0035825	78.51	gold quality
thyroid gland	UBERON:0002046	77.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

65 targeting ZNF626, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-548D-3P	99.87	70.67	4362

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000099025

Paralogs (18): ZNF430 (ENSG00000118620), ZNF92 (ENSG00000146757), ZNF66 (ENSG00000160229), ZNF22 (ENSG00000165512), ZNF680 (ENSG00000173041), ZNF114 (ENSG00000178150), ZFP41 (ENSG00000181638), ZNF730 (ENSG00000183850), ZNF479 (ENSG00000185177), ZNF431 (ENSG00000196705), ZNF100 (ENSG00000197020), ZNF257 (ENSG00000197134), ZNF98 (ENSG00000197360), ZNF675 (ENSG00000197372), ZNF273 (ENSG00000198039), ZNF737 (ENSG00000237440), ZNF253 (ENSG00000256771), ZNF723 (ENSG00000268696)

Protein

Protein identifiers

Zinc finger protein 626 — Q68DY1 (reviewed: Q68DY1)

All UniProt accessions (2): Q68DY1, M0QY39

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q68DY1-1	1	yes
Q68DY1-2	2
Q68DY1-3	3

RefSeq proteins (2): NP_001070143, NP_660340 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050636	C2H2-ZF_domain-containing	Family

Pfam: PF00096, PF01352

UniProt features (23 total): zinc finger region 12, sequence variant 6, splice variant 3, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q68DY1-F1	71.50	0.14

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 62 (showing top): chr19p12, BASAKI_YBX1_TARGETS_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, HATADA_METHYLATED_IN_LUNG_CANCER_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ASH1L_TARGET_GENES, CEBPZ_TARGET_GENES, EBNA1BP2_TARGET_GENES, PRKDC_TARGET_GENES, TAF9B_TARGET_GENES, TRIP13_TARGET_GENES, ZNF184_TARGET_GENES, MIR616_5P, MIR371B_5P, MIR373_5P

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

376 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF626	ANKRD55	Q3KP44	593
ZNF626	PRTFDC1	Q9NRG1	487
ZNF626	GOLGA8J	A6NMD2	407
ZNF626	OR2AE1	Q8NHA4	403
ZNF626	CDCP2	Q5VXM1	392
ZNF626	L3HYPDH	Q96EM0	365
ZNF626	MRI1	Q9BV20	358
ZNF626	DYNLT3	P51808	352
ZNF626	CCDC73	Q6ZRK6	348
ZNF626	MAMLD1	Q13495	338
ZNF626	CSTL1	Q9H114	323
ZNF626	LRCH2	Q5VUJ6	313
ZNF626	NME4	O00746	306
ZNF626	PCDHGA9	Q9Y5G4	304
ZNF626	EAPP	Q56P03	302

IntAct

5 interactions, top by confidence:

A	B	Type	Score
ZNF626	“espF	psi-mi:“MI:0915”(physical association)	0.370
ECE1	ZNF626	psi-mi:“MI:0915”(physical association)	0.370
FHL2	ZNF626	psi-mi:“MI:0915”(physical association)	0.000
ZNF626	ID3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (7): ZNF626 (Negative Genetic), ZNF626 (Negative Genetic), ZNF626 (Negative Genetic), ZNF626 (Affinity Capture-MS), ZNF626 (Affinity Capture-RNA), ZNF626 (Two-hybrid), ID3 (Two-hybrid)

ESM2 similar proteins: A6NK75, A6NNF4, A6NP11, A8MTY0, A8MUV8, B4DXR9, C9JN71, O75346, O75373, O95780, P0CJ79, P0DKX0, P0DPD5, P17019, P17035, P35789, Q03923, Q03938, Q08AN1, Q14593, Q15928, Q3SXZ3, Q3ZCX4, Q5MCW4, Q5R9S5, Q5RER9, Q68DY1, Q6JLC9, Q6ZMV8, Q6ZN06, Q6ZN08, Q6ZNA1, Q76KX8, Q86T29, Q86V71, Q8IYN0, Q8N4W9, Q8N7M2, Q8NEM1, Q8TD23

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — NPC.

Clinical variants and AI predictions

ClinVar

117 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	92
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

961 predictions. Top by Δscore:

Variant	Effect	Δscore
19:20646266:A:AC	donor_gain	1.0000
19:20646267:A:C	donor_gain	1.0000
19:20646318:T:A	donor_gain	1.0000
19:20625646:CATTA:C	acceptor_gain	0.9900
19:20625648:TTA:T	acceptor_gain	0.9900
19:20625649:TA:T	acceptor_gain	0.9900
19:20625651:C:CC	acceptor_gain	0.9900
19:20645278:CTCAG:C	donor_gain	0.9900
19:20645679:CCTA:C	donor_loss	0.9900
19:20645680:CTA:C	donor_loss	0.9900
19:20645682:A:C	donor_loss	0.9900
19:20645683:CCT:C	donor_loss	0.9900
19:20645777:TAC:T	acceptor_gain	0.9900
19:20645777:TACC:T	acceptor_loss	0.9900
19:20645779:CCTGT:C	acceptor_loss	0.9900
19:20645780:C:G	acceptor_loss	0.9900
19:20645781:T:G	acceptor_loss	0.9900
19:20646262:A:AC	donor_gain	0.9900
19:20646263:C:CC	donor_gain	0.9900
19:20646274:CTCA:C	donor_loss	0.9900
19:20646275:TCA:T	donor_loss	0.9900
19:20646276:C:CG	donor_loss	0.9900
19:20646277:ACC:A	donor_loss	0.9900
19:20646278:C:T	donor_loss	0.9900
19:20646402:GTCC:G	acceptor_gain	0.9900
19:20646404:CC:C	acceptor_gain	0.9900
19:20646404:CCCT:C	acceptor_loss	0.9900
19:20646405:CC:C	acceptor_gain	0.9900
19:20646405:CCTGA:C	acceptor_loss	0.9900
19:20646406:C:A	acceptor_loss	0.9900

AlphaMissense

3512 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:20624995:G:C	F294L	0.983
19:20624995:G:T	F294L	0.983
19:20624997:A:G	F294L	0.983
19:20624575:G:C	F434L	0.981
19:20624575:G:T	F434L	0.981
19:20624577:A:G	F434L	0.981
19:20624659:A:C	F406L	0.977
19:20624659:A:T	F406L	0.977
19:20624661:A:G	F406L	0.977
19:20624726:A:G	L384P	0.976
19:20624743:G:C	F378L	0.976
19:20624743:G:T	F378L	0.976
19:20624745:A:G	F378L	0.976
19:20624911:A:C	F322L	0.976
19:20624911:A:T	F322L	0.976
19:20624913:A:G	F322L	0.976
19:20625163:A:C	F238L	0.973
19:20625163:A:T	F238L	0.973
19:20625165:A:G	F238L	0.973
19:20625079:A:C	F266L	0.972
19:20625079:A:T	F266L	0.972
19:20625081:A:G	F266L	0.972
19:20624827:A:C	F350L	0.969
19:20624827:A:T	F350L	0.969
19:20624829:A:G	F350L	0.969
19:20624990:C:G	R296P	0.969
19:20624491:A:C	F462L	0.967
19:20624491:A:T	F462L	0.967
19:20624493:A:G	F462L	0.967
19:20625247:A:C	F210L	0.952

dbSNP variants (sampled 300 via entrez): RS1000030527 (19:20651553 G>A), RS1000140112 (19:20645642 T>A), RS1000221820 (19:20657752 C>A), RS1000342226 (19:20663386 G>C), RS1000607368 (19:20626522 A>G,T), RS1000748233 (19:20620671 A>C,G), RS1000868328 (19:20647369 C>G,T), RS1000917051 (19:20640461 C>A), RS1001037430 (19:20652909 A>G), RS1001093812 (19:20646877 C>A,T), RS1001140467 (19:20634421 A>T), RS1001361008 (19:20646505 C>T), RS1001549770 (19:20647070 T>C), RS1001589151 (19:20639647 G>A), RS1001937386 (19:20621504 A>G)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:109730

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), aortic valve disease 1 (MONDO:0024523)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001859_51	Thiazide-induced adverse metabolic effects in hypertensive patients	7.000000e-06
GCST003542_60	Night sleep phenotypes	1.000000e-06
GCST003901_5	Cognitive decline (age-related)	7.000000e-07

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, affects expression	3
triphenyl phosphate	affects expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	increases expression	1
aflatoxin B2	increases methylation	1
cupric oxide	increases expression	1
di-n-butylphosphoric acid	affects expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW69	HEK293 eGFP-ZNF626	Transformed cell line	Female

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists